API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/01/31/2820948/0/en/Algernon-Pharmaceuticals-Receives-Notice-of-Intention-to-Grant-from-Chinese-Patent-Office-for-Repirinast-to-Treat-CKD.html
https://www.globenewswire.com//news-release/2023/11/30/2788453/0/en/Algernon-Pharmaceuticals-Receives-Notice-of-Intention-to-Grant-from-Chinese-Patent-Office-for-Repirinast-to-Treat-NASH-and-NAFLD.html
https://www.globenewswire.com//news-release/2023/11/08/2776069/0/en/Algernon-Pharmaceuticals-Receives-Japanese-Patent-Notice-of-Allowance-for-Treatment-of-NASH-with-Repirinast.html
https://www.globenewswire.com/news-release/2022/07/11/2477137/0/en/Algernon-Pharmaceuticals-Provides-Update-on-its-Planned-Phase-1-Repirinast-Chronic-Kidney-Disease-Study.html
https://www.globenewswire.com/news-release/2022/04/26/2428910/0/en/Algernon-Pharmaceuticals-Announces-Lead-Chronic-Kidney-Disease-Drug-Repirinast-Reduced-Fibrosis-by-56-in-a-Preclinical-NASH-Study.html